FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a kit for lung cancer cell sensitisation to cisplatin. The declared kit comprises a first composition containing a therapeutically effective amount of sodium metaarsenite, and a second composition containing a therapeutically effective amount of cisplatin. Also, the invention refers to using the therapeutically effective amount of sodium metaarsenite for lung cancer cell sensitisation in a patient treated with cisplatin.
EFFECT: invention provides increasing the therapeutic effectiveness with a reduced risk of side effects.
10 cl, 4 tbl, 3 dwg, 1 ex
